Drugs / Ritobegron
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02256722 | Oct → Nov 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02256735 | Aug → Dec 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259907 | May 2003 → Feb 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00742833 | — | overactive bladder | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01003405 | — | overactive bladder | Kissei Pharmaceutical Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01004315 | — | overactive bladder | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2010-07-02 | Kissei Pharmaceutical Co., Ltd. | Results 「KUC-7483」の第Ⅲ相臨床試験の成績について kissei.co.jp ↗
過活動膀胱治療薬「KUC-7483」の第Ⅲ相臨床試験において、本薬の有効性について期待した結果が得られなかったことをお知らせいたします。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-07-02 | Kissei Pharmaceutical Co., Ltd. | 「KUC-7483」の第Ⅲ相臨床試験の成績について kissei.co.jp ↗ |
| 2002-11-29 | Kissei Pharmaceutical Co., Ltd. | キッセイ薬品、新しい頻尿･尿失禁治療剤の候補物質「KUC-7483」をベーリンガーインゲルハイムにライセンス導出 kissei.co.jp ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ritobegron | “Study to investigate the effect of Ritobegron CL (KUC 7483 CL) on the QT/QTc interval of the ECG in comparison to placebo and moxifloxacin” NCT02256735 ↗1“a single oral dose of 320 mg ritobegron administered alone or with a pre- and comedication with bisoprolol, propranolol and acipimox” NCT02256722 ↗ |
| Known as | KUC 7483 | “Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (40 to 400 mg) of KUC-7483 Tablets” NCT02259907 ↗4“Study to investigate safety, tolerability and pharmacokinetics of KUC 7483” NCT02259907 ↗ |
| Known as | KUC 7483 CL | “Study to investigate the effect of Ritobegron CL (KUC 7483 CL) on the QT/QTc interval of the ECG in comparison to placebo and moxifloxacin” NCT02256735 ↗ |
| Known as | Ritobegron Cl | “Study to investigate the effect of Ritobegron CL (KUC 7483 CL) on the QT/QTc interval of the ECG in comparison to placebo and moxifloxacin” NCT02256735 ↗ |
| Action | Activate | “Beta-3 adrenergic receptor agonist” CHEMBL2107773 ↗ |
| Modality | Small molecule | — CHEMBL2107773 ↗ |
| Route | Oral | “a single oral dose of 320 mg ritobegron administered alone” NCT02256722 ↗ |
| Target | ADRB3 | “Beta-3 adrenergic receptor agonist” CHEMBL2107773 ↗ |